HRP20161474T1 - Sastavi prokariotske fenilalanin amonij-liaze i metode za liječenje raka koje koriste ove sastave - Google Patents

Sastavi prokariotske fenilalanin amonij-liaze i metode za liječenje raka koje koriste ove sastave Download PDF

Info

Publication number
HRP20161474T1
HRP20161474T1 HRP20161474TT HRP20161474T HRP20161474T1 HR P20161474 T1 HRP20161474 T1 HR P20161474T1 HR P20161474T T HRP20161474T T HR P20161474TT HR P20161474 T HRP20161474 T HR P20161474T HR P20161474 T1 HRP20161474 T1 HR P20161474T1
Authority
HR
Croatia
Prior art keywords
pharmaceutical composition
cancer
avpal
phenylalanine
variant
Prior art date
Application number
HRP20161474TT
Other languages
English (en)
Croatian (hr)
Inventor
Michel C. Vellard
Paul A. Fitzpatrick
Emil D. Kakkis
Daniel J. Wendt
Mubarack Muthalif
Sean M. Bell
Augustus O. Okhamafe
Original Assignee
Biomarin Pharmaceutical Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40363135&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20161474(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biomarin Pharmaceutical Inc. filed Critical Biomarin Pharmaceutical Inc.
Publication of HRP20161474T1 publication Critical patent/HRP20161474T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HRP20161474TT 2007-08-17 2008-08-15 Sastavi prokariotske fenilalanin amonij-liaze i metode za liječenje raka koje koriste ove sastave HRP20161474T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6612507P 2007-08-17 2007-08-17
EP08795357.6A EP2175875B1 (en) 2007-08-17 2008-08-15 Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
PCT/US2008/009765 WO2009025760A2 (en) 2007-08-17 2008-08-15 Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof

Publications (1)

Publication Number Publication Date
HRP20161474T1 true HRP20161474T1 (hr) 2016-12-30

Family

ID=40363135

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20161474TT HRP20161474T1 (hr) 2007-08-17 2008-08-15 Sastavi prokariotske fenilalanin amonij-liaze i metode za liječenje raka koje koriste ove sastave

Country Status (23)

Country Link
US (4) US7537923B2 (enExample)
EP (1) EP2175875B1 (enExample)
JP (1) JP5584120B2 (enExample)
CN (1) CN101803492B (enExample)
AR (2) AR067972A1 (enExample)
AU (1) AU2008289549B2 (enExample)
BR (2) BR122018072594B8 (enExample)
CA (1) CA2687028C (enExample)
CL (1) CL2008002390A1 (enExample)
CY (1) CY1118222T1 (enExample)
DK (1) DK2175875T3 (enExample)
ES (1) ES2602618T3 (enExample)
HR (1) HRP20161474T1 (enExample)
HU (1) HUE029510T4 (enExample)
LT (1) LT2175875T (enExample)
MX (1) MX2009012261A (enExample)
PE (1) PE20090605A1 (enExample)
PL (1) PL2175875T3 (enExample)
PT (1) PT2175875T (enExample)
RU (2) RU2553343C2 (enExample)
SI (1) SI2175875T1 (enExample)
TW (1) TWI418787B (enExample)
WO (1) WO2009025760A2 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7537923B2 (en) * 2007-08-17 2009-05-26 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
US8796206B2 (en) * 2007-11-15 2014-08-05 Amgen Inc. Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration
WO2010014225A2 (en) 2008-07-30 2010-02-04 Biomarin Pharmaceutical Inc. Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase
WO2011078667A2 (en) 2009-12-22 2011-06-30 Dsm Ip Assets B.V. Method of finding a biocatalyst having ammonia lyase activity
EP4062928A3 (en) 2010-02-04 2022-11-30 BioMarin Pharmaceutical Inc. Prokaryotic phenylalanine ammonia-lyases and their use for treating phenylketonuria and hyperphenylalaninemia
WO2012075173A2 (en) 2010-12-01 2012-06-07 Board Of Regents The University Of Texas System Compositions and method for deimmunization of proteins
EP3222288A1 (en) * 2012-07-27 2017-09-27 University of North Texas Genetically modified probiotic for the treatment of phenylketonuria (pku) disease
PL2986722T3 (pl) 2013-04-18 2019-10-31 Codexis Inc Skonstruowane polipeptydy amoniakoliazy fenyloalaniny
BR112016011195A2 (pt) 2013-11-18 2017-09-19 Rubius Therapeutics Inc Células eritroides enucleadas e seus métodos de fabricação, composição farmacêutica e seu uso, uso de uma população de células eritroides, biorreator, mistura de células e dispositivo médico
CN106456744A (zh) 2014-04-01 2017-02-22 鲁比厄斯治疗法股份有限公司 用于免疫调节的方法和组合物
EP3145536B1 (en) 2014-04-16 2021-10-27 Codexis, Inc. Engineered tyrosine ammonia lyase
EP3137103B1 (en) 2014-04-29 2021-10-20 Bio-Cancer Treatment International Ltd. Methods and compositions for modulating the immune system with arginase i
EP3169791A1 (en) 2014-07-14 2017-05-24 Danmarks Tekniske Universitet Processes for the production of hydroxycinnamic acids using polypeptides having tyrosine ammonia lyase activity
CA2970638A1 (en) 2014-12-22 2016-06-30 Codexis, Inc. Human alpha-galactosidase variants
JP6994018B2 (ja) 2016-07-26 2022-01-14 バイオマリン ファーマシューティカル インコーポレイテッド 新規アデノ随伴ウイルスキャプシドタンパク質
IT201600086488A1 (it) * 2016-08-22 2018-02-22 St Microelectronics Srl Dispositivo a semiconduttore e corrispondente procedimento
AU2018217495B2 (en) * 2017-02-13 2021-03-04 Codexis, Inc. Engineered phenylalanine ammonia lyase polypeptides
KR20210008501A (ko) 2018-05-09 2021-01-22 바이오마린 파머수티컬 인크. 페닐케톤뇨증을 치료하는 방법
TW202005978A (zh) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 新穎肝靶向腺相關病毒載體
EP3807409A4 (en) 2018-06-12 2022-08-03 Codexis, Inc. Engineered tyrosine ammonia lyase
AU2019397401A1 (en) 2018-12-14 2021-06-17 Codexis, Inc. Engineered tyrosine ammonia lyase
MY207075A (en) 2018-12-20 2025-01-28 Codexis Inc Human alpha-galactosidase variants
CN113727733B (zh) 2019-02-14 2023-01-24 索姆创新生物技术公司 用于治疗苯丙酮尿症的氨苯蝶啶或诺拉曲塞
JP2022543611A (ja) * 2019-08-07 2022-10-13 ラクテン・メディカル，インコーポレイテッド セツキシマブ－ｉｒ７００コンジュゲート組成物
BR112022003705A2 (pt) 2019-08-30 2022-05-24 Codexis Inc Lipase recombinante, composição, sequência de polinucleotídeo recombinante, vetor de expressão, composição farmacêutica para o tratamento de insuficiência pancreática, célula hospedeira, métodos para produzir uma lipase recombinante e para tratar e/ou prevenir os sintomas de insuficiência pancreática, e, uso
MX2022007399A (es) 2019-12-20 2022-09-19 Codexis Inc Variantes de alfa-glucosidasa ácida diseñadas.
EP4103711A4 (en) 2020-02-04 2024-02-28 Codexis, Inc. Engineered leucine decarboxylases
TW202144575A (zh) 2020-04-03 2021-12-01 美商拜奧馬林製藥公司 使用ａａｖ及治療調配物之苯酮尿症治療
JP2023539634A (ja) 2020-08-28 2023-09-15 コデクシス， インコーポレイテッド 操作されたアミラーゼバリアント
AU2021334371A1 (en) 2020-08-28 2023-03-09 Codexis, Inc. Engineered protease variants
WO2022245924A1 (en) 2021-05-19 2022-11-24 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating adolescent subjects
AU2022279241A1 (en) 2021-05-21 2023-11-30 Syntis Bio, Inc. Engineered methionine gamma lyase variants
JP2024540358A (ja) 2021-11-01 2024-10-31 シンティス バイオ，インコーポレイティド 工学操作ロイシン脱炭酸酵素
CN115873837A (zh) * 2022-11-18 2023-03-31 安徽盈科生物科技有限公司 高表达的新型的苯丙氨酸解氨酶
CN118931888A (zh) * 2023-05-09 2024-11-12 重庆派金生物科技有限公司 苯丙氨酸裂解酶突变体及其偶联物或其药学上可接受的盐
GB202307239D0 (en) 2023-05-15 2023-06-28 Evox Therapeutics Ltd Gene therapies for Phenylketonuria
WO2025106759A1 (en) 2023-11-17 2025-05-22 Biomarin Pharmaceutical Inc. Conjugates of phenylalanine ammonia-lyase and poegma and methods for their use

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4252822A (en) * 1979-12-26 1981-02-24 Children's Hospital Medical Center Method for treating phenylketonuria
US4562151A (en) 1983-09-06 1985-12-31 Monsanto Company Stabilization of L-phenylalanine ammonia-lyase enzyme
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
WO1994013817A1 (en) 1992-12-04 1994-06-23 Me Medical Enzymes Ag Genetically engineered glutaminase and its use in antiviral and anticancer therapy
US5212939A (en) * 1991-12-04 1993-05-25 Pratt Jr John M Marine mooring swivel fitting
JP2930723B2 (ja) * 1992-11-19 1999-08-03 アンティキャンサー インコーポレーテド 抗メチオニン化学療法における抗腫瘍薬としてのメチオニナーゼの使用
DK75593D0 (enExample) 1993-06-25 1993-06-25 Novo Nordisk As
KR0164757B1 (ko) * 1995-06-13 1999-01-15 김광호 공조장치의 살균집진장치와 그 방법
ATE455171T1 (de) * 1995-09-21 2010-01-15 Genentech Inc Varianten des menschlichen wachstumshormons
CU22585A1 (es) 1995-11-17 1999-11-03 Centro Inmunologia Molecular Anticuerpos monoclonales antiidiótipos (ab2) de tipo igg con alta conectividad idiotípica y composiciones farmacéuticas que los contienen. su uso como inmunoreguladores de la respuesta inmune.
US6548644B1 (en) 1997-03-10 2003-04-15 Immunex Corporation Site protected protein modification
US6183738B1 (en) * 1997-05-12 2001-02-06 Phoenix Pharamacologics, Inc. Modified arginine deiminase
US5981239A (en) 1997-09-24 1999-11-09 Great Lakes Chemical Corp. Synthesis of optically active phenylalanine analogs using Rhodotorula graminis
US6451986B1 (en) * 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
US6461849B1 (en) * 1998-10-13 2002-10-08 Novozymes, A/S Modified polypeptide
US6686164B1 (en) * 1998-10-30 2004-02-03 Novozymes A/S Low allergenic protein variants
CA2328614C (en) * 1999-02-12 2012-06-26 Biostream, Inc. Matrices for drug delivery and methods for making and using the same
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
EP1280924A2 (en) 2000-04-14 2003-02-05 University of South Carolina Research Foundation Cloning of corynebacteriaceae histidine ammonia lyase and therapeutic uses
US6967097B2 (en) * 2000-07-24 2005-11-22 Pcbu Services, Inc. Phenylalainine ammonia lyase polypeptide and polynucleotide sequences and methods of obtaining and using same
US6939941B2 (en) * 2001-09-12 2005-09-06 Toray Fine Chemicals Co., Ltd. Preparation of polysulfide compositions
JP4722396B2 (ja) 2002-02-26 2011-07-13 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー 遺伝要素の組換え方法
JP2006516095A (ja) 2002-11-14 2006-06-22 ザ スクリップス リサーチ インスティテュート 脂肪酸アミドヒドロラーゼ（ｆａａｈ）の結晶形
AU2005286763A1 (en) 2004-09-17 2006-03-30 Biomarin Pharmaceutical, Inc. Variants and chemically-modified variants of phenylalanine ammonia-lyase
EP1869174B1 (en) * 2005-03-10 2015-02-18 BASF Enzymes LLC Lyase enzymes, nucleic acids encoding them and methods for making and using them
US7534595B2 (en) 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7531341B1 (en) 2006-06-12 2009-05-12 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
DE102006032167B4 (de) 2006-07-12 2014-11-27 Evonik Degussa Gmbh Verfahren zur Herstellung von Triallylisocyanurat (TAIC)
WO2008069958A2 (en) 2006-12-01 2008-06-12 The Salk Institute For Biological Studies Substrate switched ammonia lyases and mutases
US7537923B2 (en) 2007-08-17 2009-05-26 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
WO2010014225A2 (en) 2008-07-30 2010-02-04 Biomarin Pharmaceutical Inc. Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase

Also Published As

Publication number Publication date
CL2008002390A1 (es) 2009-05-29
US7537923B2 (en) 2009-05-26
HUE029510T2 (hu) 2017-02-28
PT2175875T (pt) 2016-11-21
BRPI0811589B1 (pt) 2020-05-12
EP2175875B1 (en) 2016-10-05
ES2602618T3 (es) 2017-02-21
AR067972A1 (es) 2009-10-28
JP5584120B2 (ja) 2014-09-03
DK2175875T3 (en) 2016-11-21
WO2009025760A2 (en) 2009-02-26
AU2008289549B2 (en) 2014-02-06
HUE029510T4 (en) 2017-05-29
EP2175875A2 (en) 2010-04-21
PL2175875T3 (pl) 2017-04-28
RU2012134838A (ru) 2014-03-20
SI2175875T1 (sl) 2017-01-31
BR122018072594B8 (pt) 2021-07-27
LT2175875T (lt) 2016-12-12
BR122018072594B1 (pt) 2020-10-27
BRPI0811589B8 (pt) 2021-05-25
US7560263B2 (en) 2009-07-14
WO2009025760A3 (en) 2009-06-25
AR117389A2 (es) 2021-08-04
MX2009012261A (es) 2010-03-15
RU2009141987A (ru) 2011-05-20
CA2687028C (en) 2016-02-16
CN101803492B (zh) 2014-05-07
CN101803492A (zh) 2010-08-11
JP2010536759A (ja) 2010-12-02
AU2008289549A1 (en) 2009-02-26
CY1118222T1 (el) 2017-06-28
US7790433B2 (en) 2010-09-07
US20090047265A1 (en) 2009-02-19
PE20090605A1 (es) 2009-05-16
US20090047268A1 (en) 2009-02-19
RU2553343C2 (ru) 2015-06-10
CA2687028A1 (en) 2009-02-26
US20090263369A1 (en) 2009-10-22
US20100278802A1 (en) 2010-11-04
TW200911283A (en) 2009-03-16
TWI418787B (zh) 2013-12-11
BRPI0811589A2 (pt) 2014-10-29

Similar Documents

Publication Publication Date Title
RU2012134838A (ru) Композиции прокариотической фенилаланин-аммиак-лиазы и способы лечения рака с использованием таких композиций
Nakada et al. Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads
TWI761305B (zh) 抑制Ｈｉｆ２α基因表現之組合物及方法
Van Golen et al. Suppression of tumor recurrence and metastasis by a combination of the PHSCN sequence and the antiangiogenic compound tetrathiomolybdate in prostate carcinoma
SG11201408810TA (en) Methods of treating arthritis
SG11201909735YA (en) Therapeutic compounds and compositions, and methods of use thereof
SG11201806134SA (en) Oncolytic viral vectors and uses thereof
UA77945C2 (en) Use of bcl-2 antisense oligomers to treat and prevent bcl-2 related disorders (variants), pharmaceutical composition (variants)
JP2010536759A5 (enExample)
US9828412B2 (en) Short peptide targeting EPS8 binding with EGFR and use thereof
BRPI0514420A (pt) peptìdeo, variante do mesmo, ou um sal farmaceuticamente aceitável do mesmo, composição, uso de um peptìdeo ou de uma variante de peptìdeo, substrato, e, métodos de tratamento ou prevenção de um infecção microbiana, e de tratamento de uma ferida em um indivìduo
JP2014506135A5 (enExample)
CN113993592A (zh) 针对携带酪氨酸激酶抑制剂耐药性egfr突变的癌症的化合物
EP3120849A1 (en) Cancer stem cell proliferation inhibitor and intracellular active oxygen accumulation inducer
KR20220003546A (ko) 티로신 키나제 억제제 저항성 egfr 돌연변이를 지니는 암 세포에 대한 항종양 활성을 갖는 화합물
KR20220167770A (ko) 타겟 세포 내로 올리고뉴클레오티드를 전달하기 위한 펩타이드-지질의 결합체를 포함하는 나노입자 및 이를 포함하는 약학적 조성물
KR101454866B1 (ko) 항암 약물로에 대한 무반응성 종양의 치료 및 화학증감을 위한 ｃｋ2 저해제의 용도
EA200800011A1 (ru) Тиенопиримидиновые и тиенопиридиновые модуляторы киназы
JP7223502B2 (ja) 医薬組成物
BR0112130A (pt) Composições farmacêuticas e métodos para uso
SG11201808981XA (en) Reagents for treatment of oculopharyngeal muscular dystrophy (opmd) and use thereof
USRE45471E1 (en) Pharmaceutical composition or combination drug
SG11201908932SA (en) Process for making arylomyin ring analogs
CN113712955B (zh) 含铂化合物及其组合物和应用
CA2634902A1 (en) Anticancer agent comprising a peptide